Russian Direct Investment Fund (RDIF) Kirill Dmitriev stated on Tuesday that the review of the Gamaleya Research Institute's vaccine against COVID-19 Sputnik V's response to the new, Omicron strain of the virus will last for three weeks.
Dmitriev told CNBC that Sputnik V "has shown incredibly high efficiency against all existing mutations." He also stressed that, if necessary, the developers could produce about 100 million doses of a treatment modified to correspond better to Omicron by the end of February 2022.
The RDIF previously confirmed that making a new version of Sputnik V that would be more efficient against the new strain is in the making. Earlier, scientist Ancha Baranova said that Gamaleya's treatment possibly offers stronger protection from Omicron than other existing vaccines.
